What this trial means for you
This study is opening soon at 1 US site. It's studying GLP-1 agonists for psoriatic arthritis (psa).
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes. The main objectives it aims to answer are: To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling. To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling. Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Adult patients (age 18 and older) who present to rheumatology clinic * Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB). * Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA * Participants must have a Body Mass Index (BMI) of 30kg/m\^2 * Participants must be treated for PsA in accordance with guidelines * Have not achieved MDA in PsA patients * Have a minimum TJC \> 1 and SJC \> at baseline * Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator. Exclusion Criteria: * Any prior use of GLP-1 agonists * Inability to provide informed consent * Current participation in another PsA study * Treatment initiation by GLP-1 agonists contraindicated by FDA * Patients with hemoglobin A1c (HbA1c) \> 10 at baseline
Study sites by state
Wisconsin
- Medical College of Wisconsin/Froedtert Hosptial, Milwaukee
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.